Secretin-induced Duodenal Aspirate of Pancreatic Juice (SIDA): Utility of Commercial Genetic Analysis

Rachel E. Simpson, Michele Yip-Schneider, Katelyn F. Flick, Mazhar Soufi, Eugene P. Ceppa, Mohammad A. Al-Haddad, Jeffrey J. Easler, Stuart Sherman, John M. Dewitt, C. Max Schmidt

Research output: Contribution to journalArticle


BACKGROUND: Secretin-induced duodenal aspiration (SIDA) of pancreatic duct fluid has been proposed for pancreatic neoplasm screening in very high-risk patients. We sought to determine the clinical yield and safety of commercially-analyzed SIDA samples in patients at moderately elevated risk. PATIENTS AND METHODS: A prospectively maintained institutional database of pancreatic fluid DNA profiles was retrospectively reviewed. RESULTS: Fifty-seven patients underwent SIDA testing, most commonly for intraductal papillary mucinous neoplasms (n=43) and not otherwise specified solitary cysts (n=9). SIDA mutation yield was low compared to 37 concomitant endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) samples of pancreatic fluid: KRAS (2.5% vs. 40.0%), GNAS (2.6% vs. 11.1%) and allelic loss of heterozygosity (3.1% vs. 0%). Patients undergoing SIDA alone experienced no complications while 3 patients with concomitant EUS-FNA had post-procedural pancreatitis. CONCLUSION: The genetic yield of commercially-analyzed SIDA samples was relatively low in a moderately elevated risk cohort. SIDA testing may have a better safety profile than EUS-FNA.

Original languageEnglish (US)
Pages (from-to)4215-4221
Number of pages7
JournalAnticancer Research
Issue number8
StatePublished - Aug 1 2020


  • GNAS
  • KRAS
  • Pancreatic juice
  • pancreatic cyst
  • pancreatic neoplasms
  • secretin-induced duodenal aspiration

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Secretin-induced Duodenal Aspirate of Pancreatic Juice (SIDA): Utility of Commercial Genetic Analysis'. Together they form a unique fingerprint.

  • Cite this